Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 92.3%

Neg 0% Neu 0% Pos 92.3%

Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperform and raises the price target from $7 to $12.